Definium Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Definium Therapeutics R&D Spending Growth & History (DFTX)
Definium Therapeutics's r&d spending was $117.7M for fiscal 2025.
View full Definium Therapeutics company overviewDefinium Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $117.7M | $52.4M | +80.20% |
| 2024 | 2024-12-31 | $65.3M | $13.2M | +25.27% |
| 2023 | 2023-12-31 | $52.1M | $16.0M | +44.11% |
| 2022 | 2022-12-31 | $36.2M | $1.4M | +3.97% |
| 2021 | 2021-12-31 | $34.8M | $16.2M | +86.73% |
| 2020 | 2020-12-31 | $18.6M | — | — |
Definium Therapeutics quarterly r&d spending
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $48.7M | $18.9M | +63.26% |
| Q1 2026 | 2026-03-31 | $41.5M | $18.1M | +77.61% |
| Q4 2025 | 2025-12-31 | $33.5M | $11.8M | +54.06% |
| Q3 2025 | 2025-09-30 | $31.0M | $13.8M | +80.23% |
| Q2 2025 | 2025-06-30 | $29.8M | $15.2M | +103.54% |
| Q1 2025 | 2025-03-31 | $23.4M | $11.7M | +99.55% |
| Q4 2024 | 2024-12-31 | $21.8M | $10.2M | +88.47% |
| Q3 2024 | 2024-09-30 | $17.2M | $4.0M | +30.18% |
| Q2 2024 | 2024-06-30 | $14.6M | −$132,000 | −0.89% |
| Q1 2024 | 2024-03-31 | $11.7M | −$894,000 | −7.10% |
| Q4 2023 | 2023-12-31 | $11.5M | $2.7M | +30.75% |
| Q3 2023 | 2023-09-30 | $13.2M | $5.4M | +69.88% |
| Q2 2023 | 2023-06-30 | $14.8M | $5.5M | +58.45% |
| Q1 2023 | 2023-03-31 | $12.6M | $2.4M | +23.03% |
| Q4 2022 | 2022-12-31 | $8.8M | −$2.1M | −18.86% |
| Q3 2022 | 2022-09-30 | $7.8M | −$1.2M | −13.83% |
| Q2 2022 | 2022-06-30 | $9.3M | $1.3M | +15.51% |
| Q1 2022 | 2022-03-31 | $10.2M | $3.4M | +50.32% |
| Q4 2021 | 2021-12-31 | $10.9M | — | — |
| Q3 2021 | 2021-09-30 | $9.0M | — | — |
| Q2 2021 | 2021-06-30 | $8.1M | — | — |
| Q1 2021 | 2021-03-31 | $6.8M | — | — |
Definium Therapeutics r&d spending trends
Over the last five fiscal years, Definium Therapeutics's r&d spending increased from $18.6M to $117.7M, a change of $99.0M. The latest reported quarter, Q2 2026, shows $48.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Definium Therapeutics source filings ↗